Stockscreener 앱 받기
16.46
2.72%
-0.46
시간 외 거래:
16.41
-0.05
-0.30%
전일 마감가:
$16.92
열려 있는:
$16.74
하루 거래량:
7.58M
Relative Volume:
3.61
시가총액:
$4.24B
수익:
$6.35B
순이익/손실:
$1.05B
주가수익비율:
7.1878
EPS:
2.29
순현금흐름:
$458.00M
1주 성능:
-7.79%
1개월 성능:
-10.01%
6개월 성능:
-16.06%
1년 성능:
+23.76%
1일 변동 폭
$15.98
$16.85
1주일 범위
$15.98
$19.05
52주 변동 폭
$10.84
$23.10
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Organon & Co. (NYSE:OGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Relative Strength Alert For Organon - Nasdaq
Organon updates outlook as FDA delays VTAMA label expansion - MSN
Organon reports FDA extension of target action date of review of Vtama sNDA - TipRanks
Organon’s VTAMA Cream FDA Review Extended to 2025 - TipRanks
Organon stock on watch as FDA delays VTAMA label (OGN:NYSE) - Seeking Alpha
FDA extends Organon's VTAMA cream review to March 2025 - Investing.com
Organon & Co (OGN) Stock Price Down 6.38% on Nov 4 - GuruFocus.com
Organon's SWOT analysis: stock outlook amid VTAMA potential and biosimilar growth - Investing.com UK
Organon & Co. (NYSE:OGN) Trading Down 4.4%Should You Sell? - MarketBeat
The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - Simply Wall St
Organon China’s License and Supply Agreement with Shanghai Bao Pharmaceuticals - Global Legal Chronicle
(OGN) Technical Pivots with Risk Controls - Stock Traders Daily
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28 - Yahoo Finance
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
Private Management Group Inc. Has $36.23 Million Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
FDA accepts Organon BLA for Prolia/Xgeva biosimilar - MSN
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023) - Yahoo Finance
Organon & Co. (NYSE:OGN) to Issue $0.28 Quarterly Dividend - MarketBeat
Organon & Co (OGN) Shares Up 5.61% on Oct 31 - GuruFocus.com
Organon: Q3 Earnings Snapshot - The Advocate
Organon & Co. Reports Strong Third Quarter 2024 Results - TipRanks
Organon Co earnings missed by $0.03, revenue topped estimates - Investing.com Australia
Organon (OGN) Q3 Earnings and Revenues Beat Estimates - MSN
Earnings call: Organon announced a revenue of $1.6 billion - Investing.com
Earnings call: Organon announced a revenue of $1.6 billion By Investing.com - Investing.com UK
Organon Reports Results for the Third Quarter Ended September 30, 2024 - BioSpace
Organon & Co Q3 2024 Earnings: EPS Soars to $1.38, Revenue Hits $1.582 Billion, Surpassing Estimates - GuruFocus.com
Organon & Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Organon Q3 2024 Earnings Preview: Dermavant purchase in focus - MSN
FDA accepts Henlius and Organon's biosimilar application By Investing.com - Investing.com South Africa
Organon Q3 2024 Earnings Preview: Dermavant purchase in focus (NYSE:OGN) - Seeking Alpha
FDA accepts Organon BLA for Prolia/Xgeva biosimilar (NYSE:OGN) - Seeking Alpha
FDA accepts Henlius and Organon's biosimilar application - Investing.com
Dermavant acquisition expands Organon’s dermatology portfolio - MSN
Organon Completes Acquisition of Dermavant - citybiz
Organon completes Dermavant Sciences acquisition - Investing.com
Organon completes Dermavant Sciences acquisition By Investing.com - Investing.com UK
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - StockTitan
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Organon & Co. (NYSE:OGN) Short Interest Up 28.2% in October - MarketBeat
Do Options Traders Know Something About Organon (OGN) Stock We Don't? - MSN
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline - Yahoo Finance
Organon & Co trades in the red for seven straight sessions - MSN
Organon & Co. (OGN) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga
Organon (Thailand) Ltd. promotes health and elevates women’s quality of life, creating change at the WEPs Awards 2024 - Nation Thailand
Organon (OGN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
YieldBoost Organon From 6.4% To 11.4% Using Options - Nasdaq
With 80% institutional ownership, Organon & Co. (NYSE:OGN) is a favorite amongst the big guns - Simply Wall St
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
0.19%
자본화:
|
볼륨(24시간):